Weiss Ratings Reiterates “Sell (E+)” Rating for 23andMe (NASDAQ:ME)

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

23andMe Stock Performance

Shares of ME stock opened at $2.86 on Friday. The company has a market capitalization of $74.70 million, a price-to-earnings ratio of -0.19 and a beta of 1.14. 23andMe has a one year low of $2.65 and a one year high of $16.52. The company’s 50-day moving average is $3.46 and its 200 day moving average is $5.18.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 145.99%.

Institutional Trading of 23andMe

Large investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in 23andMe during the fourth quarter worth approximately $26,000. Leavell Investment Management Inc. bought a new position in shares of 23andMe during the 4th quarter valued at approximately $32,000. MassMutual Private Wealth & Trust FSB purchased a new stake in 23andMe during the 4th quarter valued at $40,000. AQR Capital Management LLC increased its position in 23andMe by 145.8% during the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after acquiring an additional 263,468 shares during the last quarter. Finally, FMR LLC raised its stake in shares of 23andMe by 24.0% in the third quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares during the period. 36.10% of the stock is currently owned by institutional investors.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.